Table 1 Representative clinical trials of lipid nanoparticle–mRNA vaccines against infections and cancer

From: Lipid nanoparticles for mRNA delivery

Name

Disease

Encoded antigen

Administration route

ClinicalTrials.gov identifier

Phase

Infections

mRNA-1273

SARS-CoV-2

Spike

i.m.

NCT04470427

III (EUA and CMA)

BNT162b2

SARS-CoV-2

Spike

i.m.

NCT04368728

III (EUA and CMA)

CVnCoV

SARS-CoV-2

Spike

i.m.

NCT04652102

III

LNP-nCoVsaRNA

SARS-CoV-2

Spike

i.m.

ISRCTN17072692

I

ARCT-021

SARS-CoV-2

Spike

i.m.

NCT04728347

II

ARCoV

SARS-CoV-2

Receptor-binding domain

i.m.

ChiCTR2000034112

I

mRNA-1440

Influenza H10N8

Haemagglutinin

i.m.

NCT03076385

I

mRNA-1851

Influenza H7N9

Haemagglutinin

i.m.

NCT03345043

I

mRNA-1893

Zika virus

Pre-membrane and envelope glycoproteins

i.m.

NCT04064905

I

mRNA-1345

Respiratory syncytial virus

F glycoprotein

i.m.

NCT04528719

I

mRNA-1653

Metapneumovirus and parainfluenza virus type 3 (MPV/PIV3)

MPV and PIV3 F glycoproteins

i.m.

NCT03392389

I

mRNA-1647

Cytomegalovirus

Pentameric complex and B glycoprotein

i.m.

NCT04232280

II

mRNA-1388

Chikungunya virus

Chikungunya virus antigens

i.m.

NCT03325075

I

CV7202

Rabies virus

G glycoprotein

i.m.

NCT03713086

I

Cancer

mRNA-5671/V941

Non-small-cell lung cancer, colorectal cancer, pancreatic adenocarcinoma

KRAS antigens

i.m.

NCT03948763

I

mRNA-4157

Melanoma

Personalized neoantigens

i.m.

NCT03897881

II

mRNA-4650

Gastrointestinal cancer

Personalized neoantigens

i.m.

NCT03480152

I/II

FixVac

Melanoma

NY-ESO-1, tyrosinase, MAGE-A3, TPTE

i.v.

NCT02410733

I

TNBC-MERIT

Triple-negative breast cancer

Personalized neoantigens

i.v.

NCT02316457

I

HARE-40

HPV-positive cancers

HPV oncoproteins E6 and E7

i.d.

NCT03418480

I/II

RO7198457

Melanoma

Personalized neoantigens

i.v.

NCT03815058

II

W_ova1

Ovarian cancer

Ovarian cancer antigens

i.v.

NCT04163094

I

  1. CMA, conditional marketing authorization; EUA, Emergency Use Authorization; HPV, human papillomavirus; i.d., intradermal; i.m., intramuscular; i.v., intravenous; KRAS, Kirsten rat sarcoma 2 viral oncogene homologue; MAGE-A3, melanoma antigen family A; NY-ESO-1, New York esophageal squamous cell carcinoma 1; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TPTE, putative tyrosine-protein phosphatase.
Back to article page